头孢哌酮钠舒巴坦钠联合吸入布地奈德治疗慢性阻塞性肺疾病急性加重期患者临床疗效评价.docVIP

头孢哌酮钠舒巴坦钠联合吸入布地奈德治疗慢性阻塞性肺疾病急性加重期患者临床疗效评价 　　[摘要] 目的 探?头孢哌酮钠舒巴坦钠联合吸入布地奈德治疗慢性阻塞性肺疾病急性加重期（acute exacerbation of chronic obstructive pulmonary disease，AECOPD）患者的临床疗效。 方法 将93例AECOPD患者按照随机数字法分为对照组（n=46）与观察组（n=47）。两组均首先给予抗感染、解痉、祛痰以及平喘等常规治疗方法。对照组在此基础上加以头孢哌酮钠舒巴他钠，观察组在对照组的基础上雾化吸入布地奈德。比较两组临床疗效。 结果 观察组临床总有效率为93.62%（44/47），显著高于对照组（73.91%，34/46）（P0.05）。 结论 头孢哌酮钠舒巴坦钠联合吸入布地奈德治疗AECOPD患者的临床疗效显著，应在临床上进行推广及应用 [关键词] 慢性阻塞性肺疾病急性加重期；头孢哌酮钠舒巴坦钠；布地奈德；肺功能；炎性因子 [中图分类号] R563.9 [文献标识码] B [文章编号] 1673-9701（2017）02-0098-03 Clinical evaluation of cefoperazone sodium and sulbactam sodium combined with inhaled budesonide in treatment of patients with chronic obstructive pulmonary disease LIU Zhaoyun Department of Internal Medicine， Shandong Electric Power Central Hospital， Ji’nan 250001， China [Abstract] Objective To investigate the clinical efficacy of cefoperazone sodium and sulbactam sodium combined with inhaled budesonide in treatment of chronic obstructive pulmonary disease with acute exacerbation （AECOPD）. Methods 93 cases were randomly divided into control group（n=46） and observation group（n=47）. Both groups were first given anti-infective therapy， antispasmodic， expectorant and asthma etc conventional therapy. The control group was given cefoperazone sodium and sulbactam sodium treatment， observation group was given budesonide inhalation， the clinical efficacy were compared between two groups. Results The total effective rate of observation group was 93.62%（44/47）， significantly higher than the control group（73.91%， 34/46）（P0.05）. Conclusion Cefoperazone sodium and sulbactam sodium combined with inhaled budesonide in treatment of patients with AECOPD has significant clinical efficacy， should be the promotion and application in clinical practice. [Key words] Chronic obstructive pulmonary disease with acute exacerbation； Cefoperazone sodium and sulbactam sodium； Budesonide； Lung function； Inflammatory cytokines 　　慢性阻塞性肺疾病属于临床上较为常见的一种疾病，具有不可逆气流受限等方面的特点，且常伴随异常炎性反应的发生[1]。临床上一般选择